Context Therapeutics Inc. SEC filings CNTX
Context Therapeutics Inc. has 307 filings in SEC EDGAR's recent list, going back to Mar 19, 2021. Its latest annual report, Form ARS, was filed on Apr 28, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 5, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Aug 5, 2026 (regulation fd disclosure). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Regulation FD disclosure
|
Aug 5, 2026 | Aug 5, 2026 |
| 10-Q | Quarterly report | Aug 5, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Listing notice
|
Jul 31, 2026 | Jul 29, 2026 |
| 8-K |
Current report
Bylaw or fiscal year change, Shareholder vote results
|
Jun 26, 2026 | Jun 24, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Jun 15, 2026 | Jun 15, 2026 |
| 8-K |
Current report
Material agreement, Regulation FD disclosure
|
May 18, 2026 | May 14, 2026 |
| 10-Q | Quarterly report | May 6, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Other events
|
May 1, 2026 | Apr 30, 2026 |
| ARS | Annual report to shareholders | Apr 28, 2026 | Dec 31, 2025 |
| DEFA14A | Additional proxy material | Apr 28, 2026 | — |
| DEF 14A | Proxy statement | Apr 28, 2026 | Apr 28, 2026 |
| PRE 14A | Preliminary proxy statement | Apr 17, 2026 | Jun 24, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Apr 2, 2026 | Apr 2, 2026 |
| S-8 | Employee stock plan registration | Mar 23, 2026 | — |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Mar 23, 2026 | Mar 23, 2026 |
| 10-K | Annual report | Mar 23, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Bylaw or fiscal year change, Other events
|
Mar 13, 2026 | Mar 11, 2026 |
| 8-K |
Current report
Other events
|
Feb 27, 2026 | Feb 24, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Jan 8, 2026 | Jan 8, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Nov 5, 2025 | Nov 5, 2025 |
| 10-Q | Quarterly report | Nov 5, 2025 | Sep 30, 2025 |
| 8-K |
Current report
Material agreement, Other events
|
Oct 24, 2025 | Oct 24, 2025 |
| 424B5 | Prospectus supplement | Oct 24, 2025 | — |
| 8-K |
Current report
Other events
|
Oct 20, 2025 | Oct 17, 2025 |
| 8-K |
Current report
Listing notice
|
Sep 2, 2025 | Aug 28, 2025 |
| 10-Q | Quarterly report | Aug 6, 2025 | Jun 30, 2025 |
| 8-K |
Current report
Shareholder vote results
|
Jun 12, 2025 | Jun 12, 2025 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Jun 2, 2025 | Jun 2, 2025 |
| 10-Q | Quarterly report | May 7, 2025 | Mar 31, 2025 |
| ARS | Annual report to shareholders | Apr 15, 2025 | Dec 31, 2024 |
| DEFA14A | Additional proxy material | Apr 15, 2025 | — |
| DEF 14A | Proxy statement | Apr 15, 2025 | Jun 12, 2025 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Apr 9, 2025 | Apr 9, 2025 |
| PRE 14A | Preliminary proxy statement | Apr 4, 2025 | Jun 12, 2025 |
| S-8 | Employee stock plan registration | Mar 20, 2025 | — |
| 10-K | Annual report | Mar 20, 2025 | Dec 31, 2024 |
| 8-K |
Current report
Listing notice
|
Feb 28, 2025 | Feb 27, 2025 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Jan 14, 2025 | Jan 14, 2025 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Jan 13, 2025 | Jan 10, 2025 |
| 8-K |
Current report
Other events
|
Dec 23, 2024 | Dec 23, 2024 |
| 8-K |
Current report
Material agreement, Regulation FD disclosure, Other events
|
Dec 2, 2024 | Dec 2, 2024 |
| 424B5 | Prospectus supplement | Dec 2, 2024 | — |
| EFFECT | Filing | Nov 14, 2024 | — |
| CORRESP | Letter to the SEC | Nov 12, 2024 | — |
| UPLOAD | Letter from the SEC | Nov 12, 2024 | — |
| S-3 | Shelf registration | Nov 6, 2024 | — |
| 10-Q | Quarterly report | Nov 6, 2024 | Sep 30, 2024 |
| 8-K |
Current report
Material agreement, Regulation FD disclosure, Other events
|
Sep 23, 2024 | Sep 23, 2024 |
| 8-K |
Current report
Bylaw or fiscal year change, Shareholder vote results
|
Sep 17, 2024 | Sep 17, 2024 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Sep 4, 2024 | Sep 4, 2024 |
| 10-Q | Quarterly report | Aug 7, 2024 | Jun 30, 2024 |
| DEFA14A | Additional proxy material | Jul 24, 2024 | — |
| DEF 14A | Proxy statement | Jul 24, 2024 | Sep 17, 2024 |
| PRE 14A | Preliminary proxy statement | Jul 12, 2024 | Sep 17, 2024 |
| 8-K |
Current report
Material agreement, Regulation FD disclosure
|
Jul 10, 2024 | Jul 9, 2024 |
| 8-K |
Current report
Shareholder vote results
|
Jun 14, 2024 | Jun 13, 2024 |
| EFFECT | Filing | May 31, 2024 | — |
| 424B3 | Prospectus | May 31, 2024 | — |
| CORRESP | Letter to the SEC | May 29, 2024 | — |
| UPLOAD | Letter from the SEC | May 29, 2024 | — |
| S-3 | Shelf registration | May 24, 2024 | — |
| D | Filing | May 16, 2024 | — |
| 10-Q | Quarterly report | May 8, 2024 | Mar 31, 2024 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Regulation FD disclosure, Other events
|
May 2, 2024 | May 1, 2024 |
| ARS | Annual report to shareholders | Apr 26, 2024 | Dec 31, 2023 |
| DEFA14A | Additional proxy material | Apr 26, 2024 | — |
| DEF 14A | Proxy statement | Apr 26, 2024 | Jun 13, 2024 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Apr 1, 2024 | Apr 1, 2024 |
| S-8 | Employee stock plan registration | Mar 21, 2024 | — |
| 10-K | Annual report | Mar 21, 2024 | Dec 31, 2023 |
| 8-K |
Current report
Bylaw or fiscal year change
|
Mar 21, 2024 | Mar 19, 2024 |
| 8-K |
Current report
Material agreement, Regulation FD disclosure
|
Mar 6, 2024 | Feb 29, 2024 |
| 10-Q | Quarterly report | Nov 9, 2023 | Sep 30, 2023 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Oct 31, 2023 | Oct 31, 2023 |
| 10-Q | Quarterly report | Aug 9, 2023 | Jun 30, 2023 |
| 8-K |
Current report
Regulation FD disclosure
|
Aug 7, 2023 | Aug 7, 2023 |
| 8-K |
Current report
Other events
|
Jun 20, 2023 | Jun 15, 2023 |
| 8-K |
Current report
Shareholder vote results
|
Jun 2, 2023 | May 31, 2023 |
| 10-Q | Quarterly report | May 10, 2023 | Mar 31, 2023 |
| DEFA14A | Additional proxy material | Apr 6, 2023 | — |
| DEF 14A | Proxy statement | Apr 6, 2023 | May 31, 2023 |
| PRE 14A | Preliminary proxy statement | Mar 27, 2023 | May 31, 2023 |
| S-8 | Employee stock plan registration | Mar 22, 2023 | — |
| 10-K | Annual report | Mar 22, 2023 | Dec 31, 2022 |
| 8-K |
Current report
Results of operations, Exit or restructuring costs, Regulation FD disclosure
|
Mar 22, 2023 | Mar 17, 2023 |
| 8-K |
Current report
Regulation FD disclosure
|
Feb 6, 2023 | Feb 6, 2023 |
| 8-K |
Current report
Listing notice
|
Jan 27, 2023 | Jan 24, 2023 |
| 8-K |
Current report
Regulation FD disclosure
|
Jan 4, 2023 | Jan 4, 2023 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Dec 8, 2022 | Dec 7, 2022 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Dec 1, 2022 | Nov 29, 2022 |
| EFFECT | Filing | Nov 16, 2022 | — |
| CORRESP | Letter to the SEC | Nov 14, 2022 | — |
| 424B3 | Prospectus | Nov 14, 2022 | — |
| UPLOAD | Letter from the SEC | Nov 14, 2022 | — |
| EFFECT | Filing | Nov 10, 2022 | — |
| POS AM | Filing | Nov 9, 2022 | — |
| S-3 | Shelf registration | Nov 9, 2022 | — |
| 424B3 | Prospectus | Nov 9, 2022 | — |
| 8-K |
Current report
Regulation FD disclosure
|
Nov 9, 2022 | Nov 9, 2022 |
| 10-Q | Quarterly report | Nov 9, 2022 | Sep 30, 2022 |
| 424B3 | Prospectus | Sep 27, 2022 | — |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 27, 2022 | Sep 27, 2022 |
| 424B3 | Prospectus | Aug 11, 2022 | — |
| 10-Q | Quarterly report | Aug 11, 2022 | Jun 30, 2022 |
| 424B3 | Prospectus | Aug 2, 2022 | — |
| 8-K |
Current report
Material agreement, Regulation FD disclosure
|
Aug 2, 2022 | Aug 1, 2022 |
| 424B3 | Prospectus | Jun 3, 2022 | — |
| 8-K |
Current report
Shareholder vote results
|
Jun 3, 2022 | Jun 2, 2022 |
| 424B3 | Prospectus | May 12, 2022 | — |
| 10-Q | Quarterly report | May 11, 2022 | Mar 31, 2022 |
| 424B3 | Prospectus | Apr 12, 2022 | — |
| EFFECT | Filing | Apr 7, 2022 | — |
| POS AM | Filing | Apr 4, 2022 | — |
| DEFA14A | Additional proxy material | Apr 4, 2022 | — |
| DEF 14A | Proxy statement | Apr 4, 2022 | Jun 2, 2022 |
| 424B3 | Prospectus | Mar 23, 2022 | — |
| S-8 | Employee stock plan registration | Mar 23, 2022 | — |
| 10-K | Annual report | Mar 23, 2022 | Dec 31, 2021 |
| 8-K |
Current report
Results of operations
|
Mar 23, 2022 | Mar 23, 2022 |
| 424B3 | Prospectus | Jan 11, 2022 | — |
| 8-K |
Current report
Other events
|
Jan 10, 2022 | Jan 10, 2022 |
| 8-K |
Current report
Officer or director change, Other events
|
Jan 5, 2022 | Jan 1, 2022 |
| 424B4 | Prospectus | Dec 17, 2021 | — |
| EFFECT | Filing | Dec 16, 2021 | — |
| CORRESP | Letter to the SEC | Dec 14, 2021 | — |
| UPLOAD | Letter from the SEC | Dec 13, 2021 | — |
| S-1 | Registration statement | Dec 10, 2021 | — |
| 8-K |
Current report
Other events
|
Dec 6, 2021 | Dec 6, 2021 |
| 10-Q | Quarterly report | Dec 2, 2021 | Sep 30, 2021 |
| 8-K |
Current report
Results of operations
|
Dec 2, 2021 | Dec 2, 2021 |
| 8-K |
Current report
Officer or director change
|
Nov 1, 2021 | Nov 1, 2021 |
| 8-K |
Current report
Officer or director change, Bylaw or fiscal year change, Other events
|
Oct 22, 2021 | Oct 22, 2021 |
| SEC STAFF LETTER | Filing | Oct 20, 2021 | — |
| S-8 | Employee stock plan registration | Oct 20, 2021 | — |
| 424B4 | Prospectus | Oct 20, 2021 | — |
| EFFECT | Filing | Oct 19, 2021 | — |
| FWP | Free writing prospectus | Oct 18, 2021 | — |
| S-1/A | Amended registration statement | Oct 18, 2021 | — |
| CORRESP | Letter to the SEC | Oct 15, 2021 | — |
| CORRESP | Letter to the SEC | Oct 15, 2021 | — |
| FWP | Free writing prospectus | Sep 29, 2021 | — |
| S-1/A | Amended registration statement | Sep 29, 2021 | — |
| CORRESP | Letter to the SEC | Sep 24, 2021 | — |
| FWP | Free writing prospectus | Sep 24, 2021 | — |
| S-1/A | Amended registration statement | Sep 24, 2021 | — |
| UPLOAD | Letter from the SEC | Sep 22, 2021 | — |
| FWP | Free writing prospectus | Sep 13, 2021 | — |
| S-1/A | Amended registration statement | Sep 13, 2021 | — |
| CORRESP | Letter to the SEC | Aug 2, 2021 | — |
| CORRESP | Letter to the SEC | Aug 2, 2021 | — |
| CERT | Filing | Jul 27, 2021 | — |
| 8-A12B | Filing | Jul 23, 2021 | — |
| CORRESP | Letter to the SEC | Jul 23, 2021 | — |
| S-1/A | Amended registration statement | Jul 23, 2021 | — |
| CORRESP | Letter to the SEC | Jul 23, 2021 | — |
| CORRESP | Letter to the SEC | Jul 23, 2021 | — |
| UPLOAD | Letter from the SEC | Jul 12, 2021 | — |
| FWP | Free writing prospectus | Jul 12, 2021 | — |
| FWP | Free writing prospectus | Jul 12, 2021 | — |
| FWP | Free writing prospectus | Jul 2, 2021 | — |
| S-1/A | Amended registration statement | Jul 2, 2021 | — |
| CORRESP | Letter to the SEC | Jul 1, 2021 | — |
| CORRESP | Letter to the SEC | Jul 1, 2021 | — |
| S-1/A | Amended registration statement | Jun 16, 2021 | — |
| UPLOAD | Letter from the SEC | Jun 4, 2021 | — |
| SEC STAFF LETTER | Filing | May 27, 2021 | — |
| CORRESP | Letter to the SEC | May 27, 2021 | — |
| S-1 | Registration statement | May 27, 2021 | — |
| UPLOAD | Letter from the SEC | May 20, 2021 | — |
| DRS/A | Filing | May 3, 2021 | — |
| DRSLTR | Filing | Apr 30, 2021 | — |
| UPLOAD | Letter from the SEC | Apr 22, 2021 | — |
| DRS | Filing | Mar 22, 2021 | — |
| DRSLTR | Filing | Mar 19, 2021 | — |
Showing 174 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- CNTX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Philadelphia, PA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1842952
- Former names
- Context Therapeutics LLC (until May 3, 2021)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.